Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Jan H Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger

doi:10.1002/cpt.1124

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Clin Pharmacol Ther. 2019 Mar;105(3):598-613. doi: 10.1002/cpt.1124. Epub 2018 Sep 11.

Authors

Jan H Beumer^{1

2

3}, Edward Chu^{1

3}, Carmen Allegra⁴, Yusuke Tanigawara⁵, Gerard Milano⁶, Robert Diasio^{7

8}, Tae Won Kim⁹, Ron H Mathijssen¹⁰, Li Zhang¹¹, Dirk Arnold¹², Katsuki Muneoka¹³, Narikazu Boku¹⁴, Markus Joerger¹⁵

Affiliations

¹ Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
² Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
³ Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
⁴ University of Florida, Gainesville, Florida, USA.
⁵ Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.
⁶ Oncopharmacology Unit, Centre Antoine Lacassagne, Nice, France.
⁷ Developmental Therapeutics Program, Mayo Clinic Cancer Center, Rochester, Minnesota, USA.
⁸ Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic School of Medicine, Rochester, Minnesota, USA.
⁹ Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
¹⁰ Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
¹¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
¹² Department of Oncology, AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany.
¹³ Division of Oncology Center, Niitsu Medical Center Hospital, Niigata City, Japan.
¹⁴ Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan.
¹⁵ Department of Medical Oncology & Hematology, Cantonal Hospital, St. Gallen, Switzerland.

Abstract

5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

Publication types

Practice Guideline
Research Support, N.I.H., Extramural
Review

MeSH terms

Antimetabolites, Antineoplastic* / administration & dosage
Antimetabolites, Antineoplastic* / adverse effects
Congresses as Topic / standards
Drug Monitoring* / methods
Drug Monitoring* / standards
Fluorouracil* / administration & dosage
Fluorouracil* / adverse effects
Fluorouracil* / therapeutic use
Humans
Internationality*
Medical Oncology* / methods
Medical Oncology* / standards
Netherlands

Substances

Antimetabolites, Antineoplastic
Fluorouracil

Abstract

Publication types

MeSH terms

Substances

Grants and funding